Manuel López-Figueroa

Dr. López-Figueroa is the Chief Operating Officer of IMIDomics Inc. IMIDomics focuses on the discovery and development of new drugs for the treatment of immune-mediated inflammatory diseases.

In addition, Dr. Lopez-Figueroa is the Scientific Coordinator of the Pritzker Consortium for Research in Neuropsychiatric Disorders, a collaborative research consortium comprised of a group of leaders in psychiatry, neuroscience and genetics from Stanford University, the University of Michigan, Cornell University, the University of California at Irvine, and the HudsonAlpha Biotechnology Institute.

Dr. Lopez-Figueroa is also an Advisor to the San Francisco investment fund Bay City Capital, which he joined in 2001 and has been a Managing Director. Bay City Capital is one of the world's leading life sciences investment firms, having invested in over 100 companies and with over $1.6 billion of capital under management.

Dr. López-Figueroa has over 25 years of experience in the field of neuroscience, has won numerous awards during his academic research career and has published extensively. Dr. López-Figueroa holds a PhD in medicine and surgery, and a master's degree in molecular and cellular biology. He completed his postdoctoral work at the University of Michigan and the University of Copenhagen, Denmark.

Dr. López-Figueroa is a member of the board of directors of Cantero Therapeutics (a subsidiary of BridgeBio Pharma), and Zulia. He is also a director of Nina Capital.

First appointment as Director: 11 may 2020
Re-election: 02 september 2020

Company shares: CNMV